Company intelligence / Profile preview

Tharsis Capital

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Tharsis Capital is a New York-based investment firm that provides venture capital and private equity funding across the US and Canada. There is no evidence of their own clinical or drug development. They have invested in companies such as Genomatica (a sustainable chemicals firm with synthetic biology focus) and supported biotech spinouts such as LanzaX (synthetic biology, via LanzaTech).

Industry: Investors

Partnerships

Strategic partner for LanzaX spinout from LanzaTech

Beyond the preview

Go deeper on Tharsis Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tharsis Capital.

Explore the full profile